Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design

IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group

doi:10.1053/j.gastro.2020.07.064

Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design

IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group

Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	2013-2018.e7
Journal	Gastroenterology
Volume	159
Issue number	6
DOIs	https://doi.org/10.1053/j.gastro.2020.07.064
State	Published - Dec 2020

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1053/j.gastro.2020.07.064

Cite this

@article{5095386e0b844b099fbfce968b31ca8a,

title = "Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design",

author = "{IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group} and Abreu, {Maria T.} and Sandborn, {William J.} and Fabio Cataldi and Geert D'Haens and Feagan, {Brian G.} and Stephen Hanauer and Vipul Jairath and Peter Lakatos and Christopher Leptak and Dermot McGovern and Andrew Mulberg and Julian Panes and Asit Parikh and Laurent Peyrin-Biroulet and Walter Reinisch and Robert Riddell and David Rubin and Bruce Sands and Johannes Spleiss and Richard Strauss and Swati Tole and Juli Tomaino",

note = "Funding Information: The IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group represents expert speakers and panelists who participated in the meeting and who also served as authors in the development of the Meeting Summary. Members are as follows: Fabio Cataldi, AbbVie Inc; Geert D'Haens, Amsterdam UMC/AMC; Brian G. Feagan, University of Western Ontario, Robarts Clinical Trials, Inc; Stephen Hanauer, Northwestern University; Vipul Jairath, University of Western Ontario, Robarts Clinical Trials, Inc; Peter Lakatos, McGill University Health Center; Christopher Leptak, US Food and Drug Administration; Dermot McGovern, Cedars-Sinai Medical Center; Andrew Mulberg, Amicus Therapeutics, Inc; Julian Panes, Hospital Clinic Barcelona, IDIBAPS, CIBERehd; Asit Parikh, Takeda Pharmaceuticals; Laurent Peyrin-Biroulet, CHU de Nancy; Walter Reinisch, Medical University of Vienna; Robert Riddell, Mount Sinai Hospital; David Rubin, University of Chicago; Bruce Sands, Icahn School of Medicine at Mount Sinai; Johannes Spleiss, Tillotts Pharma AG; Richard Strauss, Janssen Research Development; Swati Tole, Genentech Inc; Juli Tomaino, US Food and Drug Administration. Maria T. Abreu and William J. Sandborn drafted the manuscript, and all authors critically reviewed, contributed important intellectual content, and approved the final draft for submission.",

year = "2020",

month = dec,

doi = "10.1053/j.gastro.2020.07.064",

language = "English (US)",

volume = "159",

pages = "2013--2018.e7",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "6",

}

TY - JOUR

T1 - Defining Endpoints and Biomarkers in Inflammatory Bowel Disease

T2 - Moving the Needle Through Clinical Trial Design

AU - IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group

AU - Abreu, Maria T.

AU - Sandborn, William J.

AU - Cataldi, Fabio

AU - D'Haens, Geert

AU - Feagan, Brian G.

AU - Hanauer, Stephen

AU - Jairath, Vipul

AU - Lakatos, Peter

AU - Leptak, Christopher

AU - McGovern, Dermot

AU - Mulberg, Andrew

AU - Panes, Julian

AU - Parikh, Asit

AU - Peyrin-Biroulet, Laurent

AU - Reinisch, Walter

AU - Riddell, Robert

AU - Rubin, David

AU - Sands, Bruce

AU - Spleiss, Johannes

AU - Strauss, Richard

AU - Tole, Swati

AU - Tomaino, Juli

N1 - Funding Information: The IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group represents expert speakers and panelists who participated in the meeting and who also served as authors in the development of the Meeting Summary. Members are as follows: Fabio Cataldi, AbbVie Inc; Geert D'Haens, Amsterdam UMC/AMC; Brian G. Feagan, University of Western Ontario, Robarts Clinical Trials, Inc; Stephen Hanauer, Northwestern University; Vipul Jairath, University of Western Ontario, Robarts Clinical Trials, Inc; Peter Lakatos, McGill University Health Center; Christopher Leptak, US Food and Drug Administration; Dermot McGovern, Cedars-Sinai Medical Center; Andrew Mulberg, Amicus Therapeutics, Inc; Julian Panes, Hospital Clinic Barcelona, IDIBAPS, CIBERehd; Asit Parikh, Takeda Pharmaceuticals; Laurent Peyrin-Biroulet, CHU de Nancy; Walter Reinisch, Medical University of Vienna; Robert Riddell, Mount Sinai Hospital; David Rubin, University of Chicago; Bruce Sands, Icahn School of Medicine at Mount Sinai; Johannes Spleiss, Tillotts Pharma AG; Richard Strauss, Janssen Research Development; Swati Tole, Genentech Inc; Juli Tomaino, US Food and Drug Administration. Maria T. Abreu and William J. Sandborn drafted the manuscript, and all authors critically reviewed, contributed important intellectual content, and approved the final draft for submission.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85097435261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097435261&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2020.07.064

DO - 10.1053/j.gastro.2020.07.064

M3 - Article

C2 - 32961246

AN - SCOPUS:85097435261

VL - 159

SP - 2013-2018.e7

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 6

ER -

Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this